Join Our Mailing List

What We Do
Preventive Program
Adult Education and Literacy
Youth Program
Legal Services Program
Health Program
Anti-Violence Program
Khalil Gibran International Academy
I Need To Be Heard!

Program Contact Information

Danny Salim
Anti-Violence Program Manager
(718) 250 - 5122


By E. Aschnu. University of the Southwest.

Table 2: Symptoms of HAND including history given by close relatives or companions Cognition Forgetfulness cheap zofran 4 mg without a prescription, difficulties concentrating buy zofran 8mg fast delivery, mental slowing (apprehension buy generic zofran 4mg line, processing) Emotional Loss of drive and initiative generic 8mg zofran, withdrawal from social activities cheap zofran 8mg overnight delivery, failure to manage the financial and administrative aspects of one’s life. Depressive mood, emotional blunting Motor Slowing and impairment of fine movements (e. Finally mutism Neuro- Slowing of psychomotor speed (e. Occasionally accompanying polyneuropathy In the terminal stages: spastic tetraplegia and dual incontinence 630 Interdisciplinary Medicine Table 4: Severity of HAND (Memorial Sloan-Kettering (MSK) Scale) (Price 1988) Stage 0 (normal) normal mental and motor function Stage 0. Intellectual and social comprehension and output are at a rudimentary level; almost or completely mute; paraparetic or paraplegic with urinary and fecal incontinence Diagnostic workup Making the diagnosis of HAND requires a synopsis of clinical information and laboratory tests. No laboratory test result on its own can warrant a diagnosis of HAND. Rather, the diagnosis requires the exclusion of other conditions (Table 5). Psychological and behavioral as well as motor signs and symptoms may be subtle in the early stages. Motor signs are often encoun- tered in the later stages (Tables 2 and 3). Formal neuropsychological cognitive testing, the gold standard, should be done. This should encompass the domains verbal/ language, attention/working memory, abstraction/executive function, learning/ recall, speed of information processing, and motor skills (Mind Exchange Group 2013). Where a trained neuropsychologist is not available, the HIV dementia scale as an easy-to-use bedside instrument may be used, but its sensitivity and specificity are limited (Morgan 2008). Laboratory tests are mainly employed to exclude differential diagnoses. The MRI may show patchy, diffuse, and relatively symmetrical hyper- intense lesions in the white matter. In addition, atrophy with enlargement of the ventricles and the extraventricular CSF spaces may be seen. However, none of these findings are specific for HAND, and the disease may evolve with a normal MRI. Unlike in PML, the white matter lesions do not affect the cortical U-fibers, i. Edema and space occupying lesions are not compatible with HAND and should raise suspicion of other conditions. CSF analysis mostly shows a normal white cell count, and with severe immunosup- pression this may even be decreased. In patients with an at least partially effective ART, CSF pleocytosis may be seen, suggesting an immunological response to HIV in the context of immune reconstitution. Total protein and albumin concentrations may be slightly elevated (blood-brain barrier disruption). Oligoclonal bands and increased IgG index indicate autochthonous immunoglobulin production within the CNS. However, these findings are non-specific, and they are frequently present even in the asymptomatic stages of HIV infection. HIV-1-associated Neurocognitive Disorder (HAND) and Myelopathy 631 In untreated patients there is a weak but statistically significant correlation of (higher) CSF viral load with HAND. However, this association is no longer true for individu- als on ART (Mc Arthur 2004, Heaton 2011). The electroencephalogram (EEG) shows no or only mild signs of generalized slowing. Moderate or severe slowing or focal arrhythmic delta activity are atypical for HAND. With a large part of the HIV+ population growing older, other types of dementia such as Alzheimer’s disease, vascular dementia, Lewy body dementia, etc. Screening and Treatment Screening for HAND is recommended in all HIV+ patients, regardless of treatment status (Mind Exchange Group 2013). This should ideally be carried out before initi- ation of ART in order to generate baseline data. Screening should be done every 6 to 24 months, according to the risk profile of the patient.

cheap zofran 4 mg line

Factor XIIa inhibitor dase depletion induces vascular dysfunction with hypertension and recombinant human albumin Infestin-4 abolishes occlusive arterial faster arterial thrombosis discount zofran 8mg without a prescription. Factor XII regulates brain barrier damage generic 4 mg zofran overnight delivery, and inflammation discount zofran 8mg on-line. Factor XII inhibition knockout mice are protected from thrombosis by increased nitric oxide reduces thrombus formation in a primate thrombosis model safe 4mg zofran. A factor XIIa inhibitory decrease thrombosis in Bdkrb2 / mice by increasing NO and antibody provides thromboprotection in extracorporeal circulation with- prostacyclin to reduce platelet spreading and glycoprotein VI activation cheap zofran 4 mg without a prescription. Meijers1,2 1Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; and 2Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands The contact pathway of coagulation consists of the proteins factor XI, factor XII, prekallikrein, and high-molecular- weight kininogen. Activation of the contact system leads to procoagulant and proinflammatory reactions. The contact system is essential for surface-initiated coagulation, as exemplified by aPTT, but there is probably no role for the contact system in initiating physiologic in vivo coagulation. However, over the last few years, there has been renewed interest, especially because of experimental evidence suggesting that the contact system contributes to thrombosis. Knockout mice deficient in one of the contact proteins were protected against artificially induced thrombosis. Furthermore, inhibiting agents such as monoclonal antibodies, antisense oligonucleotides, and small molecules were found to prevent thrombosis in rodents and primates in both venous and arterial vascular beds. Although it remains to be established whether targeting the contact system will be effective in humans and which of the contact factors is the best target for anticoagulation, it would constitute a promising approach for future effective and safe antithrombotic therapy. The contact system has a remarkable resemblance to the innate Learning Objectives 3 immune system based on the recognition molecules. Indeed, the ● To understand that the contact system consists of 4 proteins: contact system recognizes an increasing number of bacterial patho- factor XI, factor XII, PK, and HK gens and other types of microorganisms. Therefore, the contact system is part of the new method to prevent thrombosis in mice research field referred to as “immunothrombosis. In the accompanying chapters by Gailani and Key, the preclinical work in other rodents Introduction and primates and the epidemiological and clinical studies on the The contact system consists of 4 plasma proteins: factor XI, factor contact system and thrombosis are summarized. XII, prekallikrein (PK), and high-molecular-weight kininogen (HK). The proteins were recognized in the 1950s and 1960s after identification of individuals with (severely) prolonged activated Biochemistry of the contact system partial thromboplastin times (aPTTs). Originally, the proteins were The contact system consists of 3 proenzymes (factor XII, PK, and given names such as Hageman factor (factor XII), Fletcher factor factor XI) and a cofactor (HK). The domain structure of the contact (PK), Williams-Fitzgerald-Flaujeac factor (HK), and plasma throm- proteins is shown in Figure 1. The contact system assembles on boplastin antecedent (factor XI). Artificial charged surfaces and will then initiate procoagulant and proinflam- surfaces that are used in catheters or cardiopulmonary bypass will matory reactions via the intrinsic pathway of coagulation and the also lead to activation of the contact system and, over recent years, kallikrein-kinin system, respectively. HK also deficiency of one of the other contact factors is not associated with bleeding. Recently, some exciting data have become available that binds directly and, because it is in the circulation in complex with point to a role for the contact system in thrombosis. Even though the PK and factor XI, the complete contact system becomes assembled majority of the data were obtained from animal experiments, the on the surface. According to current insights, the contact system is not 60 American Society of Hematology Figure 1. Cleavage sites for activation are indicated with an arrow. The most important system on (negatively) charged surfaces results in a series of argument for this statement is the lack of a bleeding diathesis in procoagulant and proinflammatory reactions. Binding of factor XII patients deficient in factor XII, PK, or HK. Coagulation occurs to a negatively charged surface causes a conformational change of when the plasma protease activated factor VII comes into contact the protein and results in (limited) activation to factor XIIa. The Activated factor XII cleaves PK into kallikrein (Kal), which TF/factor VIIa complex can activate factor X, which can convert reciprocally activates additional factor XIIa (Figure 2). Thrombin, in turn, is involved in can activate factor XI to factor XIa, which further initiates thrombin multiple pathways, one of which is the conversion of fibrinogen into and fibrin formation. HK serves as a nonenzymatic cofactor for the fibrin, which constitutes the clot.

order 8 mg zofran amex

Labeling a study as either an efficacy or an effectiveness study zofran 4mg generic, although convenient 4 mg zofran fast delivery, is of limited value; it is more useful to consider whether the patient Statins Page 10 of 128 Final Report Update 5 Drug Effectiveness Review Project population order 8 mg zofran otc, interventions generic zofran 8 mg online, time frame zofran 4mg discount, and outcomes are relevant to one’s practice or to a particular patient. Studies anywhere on the continuum from efficacy to effectiveness can be useful in comparing the clinical value of different drugs. Effectiveness studies are more applicable to practice, but efficacy studies are a useful scientific standard for determining whether characteristics of different drugs are related to their effects on disease. Systematic reviews thoroughly cover the efficacy data in order to ensure that decision makers can assess the scope, quality, and relevance of the available data. This thoroughness is not intended to obscure the fact that efficacy data, no matter how large the quantity, may have limited applicability to practice. Clinicians can judge the relevance of studies’ results to their practice and should note where there are gaps in the available scientific information. Unfortunately, for many drugs there exist few or no effectiveness studies and many efficacy studies. Yet clinicians must decide on treatment for patients who would not have been included in controlled trials and for whom the effectiveness and tolerability of the different drugs are uncertain. Systematic reviews indicate whether or not there exists evidence that drugs differ in their effects in various subgroups of patients, but they do not attempt to set a standard for how results of controlled trials should be applied to patients who would not have been eligible for them. With or without an evidence report, these decisions must be informed by clinical judgment. In the context of development of recommendations for clinical practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of an intervention are based on strong evidence from clinical studies. Judgment, reasoning, and applying one’s values under conditions of uncertainty must also play a role in decision making. Users of an evidence report must also keep in mind that not proven does not mean proven not; that is, if the evidence supporting an assertion is insufficient, it does not mean the assertion is untrue. The quality of the evidence on effectiveness is a key component, but not the only component, in making decisions about clinical policy. Additional criteria include acceptability to physicians and patients, potential for unrecognized harm, applicability of the evidence to practice, and consideration of equity and justice. Scope and Key Questions The purpose of this review is to compare the efficacy and adverse effects of different statins. The Oregon Evidence-based Practice Center wrote preliminary key questions, identifying the populations, interventions, and outcomes of interest, and based on these, the eligibility criteria for studies. These were reviewed and revised by representatives of organizations participating in the Drug Effectiveness Review Project. The participating organizations of the Drug Effectiveness Review Project are responsible for ensuring that the scope of the review reflects the populations, drugs, and outcome measures of interest to clinicians and patients. Since the last review, the participating organizations have decided to include pediatric population and fixed- dose combination products containing a statin and another lipid-lowering drug. The participating organizations approved the following key questions to guide this review: Statins Page 11 of 128 Final Report Update 5 Drug Effectiveness Review Project 1. How do statins and fixed-dose combination products containing a statin and another lipid-lowering drug compare in their ability to reduce low-density lipoprotein cholesterol? Are their doses for each statin or fixed-dose combination product containing a statin and another lipid-lowering drug that produce similar percent reduction in low-density lipoprotein cholesterol between statins? Is there a difference in the ability of a statin or fixed-dose combination product containing a statin and another lipid-lowering drug to achieve National Cholesterol Education Panel goals? How do statins and fixed-dose combination products containing a statin and another lipid-lowering drug compare in their ability to raise high-density lipoprotein cholesterol? Are there doses for each statin or fixed-dose combination product containing a statin and another lipid-lowering drug that produce similar percent increase in high-density lipoprotein cholesterol between statins? Is there a difference in the ability of a statin or fixed-dose combination product containing a statin and another lipid-lowering drug to achieve National Cholesterol Education Panel goals? How do statins and fixed-dose combination products containing a statin and another lipid-lowering drug compare in their ability to reduce the risk of nonfatal myocardial infarction, coronary heart disease (angina), coronary heart disease mortality, all-cause mortality, stroke, hospitalization for unstable angina, or need for revascularization (coronary artery bypass graft, angioplasty, or stenting)? Are there differences in effectiveness of statins and fixed-dose combination products containing a statin and another lipid-lowering drug in different demographic groups or in patients with comorbid conditions (e. Are there differences in the harms of statins or fixed-dose combination products containing a statin and another lipid-lowering drug when used in the general population of children or adults?

discount 8mg zofran with amex

The estimated frequency F(p) ≈ 10−4 based on Butz and Bevan (1998) refers to the frequency of individual T cells responding to a peptide trusted zofran 4 mg. It was not clear from that study how many different T cell clones were involved buy 8mg zofran free shipping. It is challenging to estimate the number of different clones SPECIFICITY AND CROSS-REACTIVITY 51 from the naive repertoire that respondtoaparticular peptide order zofran 8 mg fast delivery, although recent technical breakthroughs may soon provide more data (Yewdell and Bennink 1999) buy 8mg zofran with amex. Among the better studies available discount 4mg zofran visa, Maryanski et al. The response in this case may have been limited because the human MHC molecule is similar to mouse MHC molecules, causing the tested peptide to be seen as similar to a self-peptide of the mouse. In another study by the same research group, the clonal diversity of CTLs responding to a Plasmodium berghei peptide was much higher than against HLA-CW3, but the methods did not permit a comparable estimate for the number of clones (Jaulin et al. Humans have about 1011 Tcells compared with about 108 Tcells in mice. If the frequency, F(p),ofTcells responding to a peptide is about the same in humans as in mice, then, from equation (4. The value estimated above is each TCR binding P(t) ≈ 5 × 105 different peptides. How can such high cross-reactivity be reconciled with observed speci- ficity? First, the probability of any particular T cell cross-reacting with two different epitopes remains low. If a T cell reacts with one epitope, the probability that it reacts with asecond, randomly chosen epitope is P(t)/N ≈ 10−4. Second, the observed specificity has to do with the number of differ- ent T cell clones that actually expand in response to an epitope. The number of expanding clones is certainly lower than the potential set of clones that bind sufficiently strongly to stimulate a response (Yewdell and Bennink 1999). Competition between clones for the epitope and for other stimulatory signals limits clonal expansion. Here I simply note that the broad and highly cross- reactive repertoire of the naive T cells may be important for fighting primary exposure, much as the natural antibodies provide background protection against first infection. The secondary or memory response may be much narrower because it is limited to those binding clones that received additional stimulatory signals during primary infection. By their calculation only ∼1/5 of potential epitopes survive proteolytic digestion and transport to the endoplasmic reticulum for loading onto MHC molecules; of these, only ∼1/200 bind MHC molecules above the threshold affinity required for immunogenicity; finally, limitations in the TCR repertoire for binding peptide-MHC complexes cause ∼1/2 of presented peptides tostimulatearesponse. This is only a very rough approximation based on the limited data available. MHC presentation and TCR binding are just the first steps in a T cell response. Typically, several TCRs mayreceive sufficient stimulation, but only a subset continue to develop strong clonal expansion. I discuss the factors that influence which clones do and do not expand in chapter 6. Different hosts vary in several at- tributes of immune recognition; thus the dominant epitopes will change from one host to the next even for an unvarying parasite. The MHC class I and II molecules arethemoststrikingly polymor- phic of all human loci. The three main class I loci for presenting pep- tides, designated A, B, and C, currently have 175, 349, and 90 alleles de- scribed, respectively. The class II molecules have separate designations for individual components of each molecule. The highly polymorphic components tend to be in the β1 chains that contact bound peptides (Marsh et al. The β1 chains for the DR, DQ, and DP class II mole- culescurrently have 246, 44, and 86 alleles described, respectively. The IMGT/HLA on-line database lists recent allelic counts, as described in Robinson et al.

9 of 10 - Review by E. Aschnu
Votes: 63 votes
Total customer reviews: 63


The Arab-American Family Support Center is a 501(c)3 non-profit, non-sectarian organization that provides culturally and linguistically sensitive services to immigrant communities throughout New York City.  © 2017 All Rights Reserved.

AAFSC Brooklyn
150 Court Street, 3rd Flr
Brooklyn, NY 11201
T: 718 - 643 - 8000
F: 718 - 797 - 0410
E: info@aafscny.org
AAFSC Queens
37-10 30th Street, 2nd Fl.

Queens, NY 11101
T: 718 - 937 - 8000
F: 347 - 808 - 8778
AAFSC @ the Family Justice Centers
FJC Bronx (718) 508-1220
FJC Brooklyn (718) 250 - 5035
FJC Manhattan (212) 602-2800
FJC Queens (718) 575 - 4500
FJC Staten Island (718) 697 - 4300